BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22569237)

  • 1. Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone.
    Arita H; Kinoshita M; Oshino S; Kitamura T; Otsuki M; Kasayama S; Shimokawa T; Shimomura I; Yoshimine T; Saitoh Y
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2741-7. PubMed ID: 22569237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas.
    Igarashi-Migitaka J; Yamada S; Hara M; Sano T; Ozawa Y; Ohtani-Kaneko R; Hirata K
    Endocr J; 2003 Aug; 50(4):459-67. PubMed ID: 14599121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gsp mutation in acromegaly and its influence on TRH-induced paradoxical GH response.
    Goto Y; Kinoshita M; Oshino S; Arita H; Kitamura T; Otsuki M; Shimomura I; Yoshimine T; Saitoh Y
    Clin Endocrinol (Oxf); 2014 May; 80(5):714-9. PubMed ID: 24111551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro short-term effects of SMS 201-995, bromocriptine and TRH on growth hormone cell morphology from human pituitary adenomas.
    García García J; Jiménez Reina L; García Luna PP; Leal Cerro A; Astorga Jiménez R; García García-Revillo J; Bernal Valls G
    Histol Histopathol; 1989 Apr; 4(2):223-33. PubMed ID: 2520459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas.
    Kim K; Arai K; Sanno N; Teramoto A; Shibasaki T
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):309-16. PubMed ID: 11298082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.
    Obari A; Sano T; Ohyama K; Kudo E; Qian ZR; Yoneda A; Rayhan N; Mustafizur Rahman M; Yamada S
    Endocr Pathol; 2008; 19(2):82-91. PubMed ID: 18629656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine and immunohistochemical studies on thyrotropin (TSH)-secreting pituitary adenomas: responses of TSH, alpha-subunit, and growth hormone to hypothalamic releasing hormones and their distribution in adenoma cells.
    Kuzuya N; Inoue K; Ishibashi M; Murayama Y; Koide Y; Ito K; Yamaji T; Yamashita K
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1103-11. PubMed ID: 1699960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRH is a tonic secretagogue in growth hormone secreting but not in nonfunctioning pituitary tumors.
    Somjen D; Tordjman K; Greenman Y; Kohen F; Ouaknine GE; Stern N
    J Endocrinol Invest; 1999 Feb; 22(2):104-8. PubMed ID: 10195376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone-secreting adenomas: pathology and cell biology.
    Lopes MB
    Neurosurg Focus; 2010 Oct; 29(4):E2. PubMed ID: 20887127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenylate cyclase of GH and ACTH producing tumors of human: activation by non-specific hormones and other bioactive substances.
    Matsukura S; Kakita T; Hirata Y; Yoshimi H; Fukase M
    J Clin Endocrinol Metab; 1977 Feb; 44(2):392-7. PubMed ID: 190256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenomas of patients with acromegaly express thyrotropin-releasing hormone receptor messenger RNA: cloning and functional expression of the human thyrotropin-releasing hormone receptor gene.
    Yamada M; Monden T; Satoh T; Satoh N; Murakami M; Iriuchijima T; Kakegawa T; Mori M
    Biochem Biophys Res Commun; 1993 Sep; 195(2):737-45. PubMed ID: 8396925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.